The debate surrounding cancer endpoints has focused on the issue of quality of life and progression. Panelists shared some of the challenges in assessing quality of life, since it can be a fickle and subjective process. The data can be hard to nail down since patients don’t always fill out the forms. The critical issues include survival rates, improved quality of life and progression of disease. Everything must be taken into consideration to determine endpoints, which is why the issue is hotly debated.
Subscribe to our e-newsletterVIEW OUR CURRENT ISSUE >
Tagshealthcare biotechnology Health Care biotech industry Biotechnology Industry FDA BIO International Convention ethanol BIO Events Plant biotechnology Intellectual Property public policy Sustainability health biofuels BIOTECH economic development renewable fuel standard patent One-on-One's
- Most Popular
Latest VideoInnovation Is... with Doug Doerfler of MaxCyte View All >